Rashid J R, Juma F D
Clinical Research Centre, Nairobi.
East Afr Med J. 1992 Jul;69(7):406-8.
In this study, the investigation of hydralazine acetylator phenotype was undertaken for the first time in African hypertensives at Kenyatta National Hospital. A total of 25 randomly selected patients with moderate to severe hypertension (diastolic pressure 105-130 mmHg), participated in the phenotyping study. The phenotyping was done by administering oral standard hydralazine dose of 150 mg/day in three divided doses. The 24 hour urinary MTP/hydralazine ratio was used to categorize patients into slow and fast acetylators. Of the patients studied 69.9% were slow acetylators while 30.4% were fast acetylators. The mean 24 hour urinary MTP/hydralazine ratio for slow acetylators was 1.01 +/- 0.95. This was significantly different from the fast acetylators where the mean 24 hour urinary MTP/hydralazine ratio was 10.6 +/- 4.4 (P < 0.001). The acetylator phenotyping divided the patients into two distinct populations and no further arbitrary method was required to divide the patients into either group.
在本研究中，首次在肯尼亚肯雅塔国家医院对非洲高血压患者进行了肼屈嗪乙酰化酶表型研究。总共25名随机选择的中度至重度高血压患者（舒张压105 - 130 mmHg）参与了表型研究。表型分析通过口服标准剂量的肼屈嗪150 mg/天，分三次给药进行。24小时尿中对甲酚/肼屈嗪比值用于将患者分为慢乙酰化者和快乙酰化者。在研究的患者中，69.9%是慢乙酰化者，而30.4%是快乙酰化者。慢乙酰化者的平均24小时尿中对甲酚/肼屈嗪比值为1.01±0.95。这与快乙酰化者有显著差异，快乙酰化者的平均24小时尿中对甲酚/肼屈嗪比值为10.6±4.4（P < 0.001）。乙酰化酶表型分析将患者分为两个不同的群体，无需进一步采用任意方法将患者分为两组。
